Cannabidiol (CBD) should be reassigned to Schedule V, the least restrictive class of the Controlled Substances Act, according to a 27-page Food and Drug Administration agency memo written earlier this year and first reported by MarijuanaMoment.com.
In the memo titled, “Basis for the Recommendation to Place Cannabidiol in Schedule V of the Controlled Subtsance Act, the FDA wrote “CBD and its salts… do not have a significant potential for abuse and could be removed from the [Controlled Substances Act].”
CBD, as with all cannabis products, is currently Schedule I, the most restrictive classification – the same as heroin and LSD and cannot be legally marketed in the United States.
The reason the FDA suggested reclassification to Schedule V instead of removal from the CSA is due to international drug treaties that require the U.S. to control the cannabis extract.
The report, which included a letter from Dr. Brett Giroir, the assistant secretary for health in the U.S. Health and Human Services Department, FDA’s parent agency, also said “if treaty obligations do not require control of CBD, or if the international controls on CBD change in the future, this recommendation will need to be promptly revisited” and CBD should be declassified.
The letter was dated May 16 but made public Sept. 28, after the DEA announced that FDA-approved Epidiolex and any potentially other cannabis drugs with no more than 0.1 percent THC could be classified as Schedule 5.
The potential for the CBD market is immense.
According to a new report released recently by the Brightfield Group, the hemp-derived CBD market (which is legal) alone will reach sales of $22 billion by 2022, outpacing cannabis sales, and surging from $591 million in 2018.
To read the memo: